TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07765888: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED PHASE 3 COMBINATION THERAPY STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE OR OLDER WITH MOD

Sponsor: Pfizer · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 375 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$6,924,204

Rescue Site Savings

+$4,579,500

Unlock Full NCT07765888 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07765888 Rescue Dossier →